Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10444497 | 0.82 | CTBP2 (0.54) | TAAR1IDO1CTBP2POLBALDH1A1 | |
| SCHEMBL30468689 | 0.80 | HTR3E (0.61) | TAAR1IDO1CTBP2POLBMAPK8 | |
| SCHEMBL19266040 | 0.80 | TAAR1 (0.52) | TAAR1IDO1CTBP2POLBMAPK8 | |
| SCHEMBL7222240 | 0.80 | CTBP2 (0.49) | TAAR1IDO1CTBP2POLBALDH1A1 | |
| SCHEMBL1985821 | 0.80 | CTBP2 (0.57) | TAAR1IDO1CTBP2POLBMAPK8 | |
| SCHEMBL8203794 | 0.80 | HTR3E (0.61) | TAAR1IDO1CTBP2POLBMAPK8 | |
| Hydrochloric Acid SCHEMBL213051 | 0.78 | HTR3E (0.59) | TAAR1IDO1CTBP2POLBMAPK8 | |
| SCHEMBL1580469 | 0.77 | CTBP2 (0.58) | TAAR1IDO1CTBP2POLBMAPK8 | |
| SCHEMBL1580471 | 0.77 | CTBP2 (0.58) | TAAR1IDO1CTBP2POLBMAPK8 | |
| SCHEMBL27619612 | 0.77 | CTBP2 (0.53) | TAAR1IDO1CTBP2POLBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-2530078-A1 | THIAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1742942-A1 | PHENYLTHIOACETIC ACID DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005097784-A1 | PHENYLTHIOACETIC ACID DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | TAAR1 3965/4885IDO1 911/4885CTBP2 1362/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | TAAR1 190/4885IDO1 244/4885CTBP2 2106/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | TAAR1 190/4885IDO1 244/4885CTBP2 2106/4885 |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | PAH, TST, MPST | TAAR1 1842/4885IDO1 3672/4885CTBP2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.